Impact Therapeutics will invest the cash from the Lilly Asia Ventures-backed round to further develop its lead cancer treatment candidate.

China-based biopharmaceutical company Impact Therapeutics has closed a $30m series C round that included Lilly Asia Ventures (LAV), a corporate venturing representative of pharmaceutical firm Eli Lilly. Venture capital firm Decheng Capital led the round, which followed a $10m series B round completed by the company in early 2016. Impact is developing treatments for life-threatening…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.